Dr Louis Allot is an expert in the clinical development of radiopharmaceuticals. He has extensive experience in developing novel radiopharmaceutical technologies from small molecules, to proteins, aptamers and…

Dr. Paloma Giangrande is an internationally recognized expert in nucleic acid therapeutics and delivery. She pioneered the use of RNA aptamers for targeted siRNA delivery beyond the liver,…

Dr Shozo Fujita is a biotechnology consultant with expertise in developing a novel aptamer platform incorporating modified nucleotide chemistries. He has previously held positions as R&D Director at Fujitsu…

Tim is an experienced executive and non-executive director, having been CEO and, previously, CFO of Proactis Holdings PLC between 2006 and 2022 and having served as fractional or transitionary CFO at…

Professor Paul Townsend is an internationally renowned scientist and academic leader in the field of cell science, drug discovery and biomarker identification to advance precision medicine. He has held…

Andrew is the Chief Financial Officer and Company Secretary at Aptamer Group. He is a Chartered Accountant (ICAEW) and brings 20 years experience in the industry with over 8…

David leads research and development activities to support customer validation assays and internal R&D at Aptamer Group. He holds a Ph.D. in Molecular Biology and has spent nearly 20…

Arron is the founder and Chief Executive Officer of Aptamer Group. Arron holds a Ph.D. in Molecular Biology and Biophysics from the University of Leeds and a B.Sc. in…

Dr Adam Hargreaves is the founder of PathCelerate Limited, a contract research pharmaceutical efficacy and safety company.  Spanning a 20-year career, he previously worked for AstraZeneca, and has interests and…